Protagen AG Appoints New Board Members to Expand Expertise in Diagnostics Commercialization

Thursday, 01 October 2015

Protagen AG, the technology leader in the development of novel molecular diagnostic and companion diagnostic tests for autoimmune diseases, has elected Dr. Dirk Ehlers, CEO of Trumpf Medical in Puchheim, to the company's Supervisory Board.

Simultaneously, Wolfgang Kintzel, Senior Investment Manager of NRW.BANK in Düsseldorf, succeeded Dr. Aristotelis Nastos as representative of NRW.BANK, and Matthias Guth, was appointed by MIG AG in Munich, to follow Michael Motschmann in his board position.

Dr. Ehlers has served in executive positions at Eppendorf, Roche Diagnostics, Evotec, Fresenius Kabi and Olympus Diagnostics and has a proven track record in the Diagnostics Industry, with deep expertise in marketing and commercialization.

According to Dr. Ehlers, "Protagen offers an outstanding technology that addresses the current needs of the autoimmune diagnostics industry, which remains many years behind oncology diagnostics in terms of new molecular content, time to market and therapy support. The Protagen technology is able to deliver novel, validated biomarkers and significantly reduce the time to market. I look forward to supporting the efforts of the company in translating its significant potential into a commercial success story."

Stefan Müllner, CEO of Protagen, added: "In order to become the leading provider of Dx and CDx for autoimmune therapy, and to foster the potential for strategic collaborations and partnerships, it is imperative that we have meaningful insight into the strategies and processes of the global diagnostic leaders. The profound expertise Dr. Ehlers will bring to this role will provide us with valuable guidance, and will help us to effectively expand our business within the growing and demanding autoimmune Dx field. Together with the expertise of Wolfgang Kintzel, executive manager at AMAXA and CEVEC before joining NRW.BANK, and Matthias Guth, with nearly two decades of experience as investment manager in the biotech industry, Protagen is backed by a Supervisory Board of distinguished industrial experts with synergistic expertise."


About Protagen – Diagnostics Differentiated

Protagen AG, headquartered in Dortmund, Germany, specializes in the development of novel diagnostic and companion diagnostic tests to provide better and earlier diagnosis of autoimmune diseases.

Protagen uses its proprietary SeroTag® biomarker platform to identify disease specific autoantibodies and is on target to become the leading provider of autoimmune diagnostic products, specifically targeting diseases with an unmet need for effective diagnostics. With pioneering bioscience techniques, extensive scientific expertise and a broad patent portfolio, Protagen works to develop its own diagnostic pipeline and partners with other organizations to develop and implement new companion diagnostic tools for better personalized treatment strategies.


Contact
Dr. Stefan Müllner
CEO
bd@protagen.com
T +49 231 9742 6300

Media Enquiries
Dr. Clare Russell
Managing Director
BioStrata
Cambridge
UK
crussell@biostratamarketing.com
T +44 1223 828200
M +44 7812 343412

Contact us